Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
OBJECTIVE: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. METHODS: Patients ha...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
|
Series: | Brazilian Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600006&lng=en&tlng=en |
id |
doaj-211e329d955147629f84288e55473d8b |
---|---|
record_format |
Article |
spelling |
doaj-211e329d955147629f84288e55473d8b2020-11-25T02:49:53ZengElsevierBrazilian Journal of Infectious Diseases1678-439117665766010.1016/j.bjid.2013.04.002S1413-86702013000600006Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral loadAna Júlia Luz0Júlia Poeta1Rafael Linden2Marina Venzon Antunes3Luiza Isola Caminha4Eduardo Sprinz5Universidade Federal do Rio Grande do SulUniversidade Federal do Rio Grande do SulUniversidade FEEVALEUniversidade FEEVALECentro Universitário Metodista do IPAUniversidade Federal do Rio Grande do SulOBJECTIVE: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. METHODS: Patients had to be on atazanavir for at least six months, undetectable viral load for a period equal to or longer than 12 months, T CD4+ lymphocyte count higher than 200 cells/mm³, and aged between 18 years and 70 years old. Exclusion criteria were pregnancy, any neurologic disease, active opportunistic disease, hepatitis or cancer. Atazanavir plasma levels were measured by ultra-performance liquid chromatography. RESULTS AND DISCUSSION: Overall, 54 patients (mean age of 47 years and 50% women) were included in the analysis. Those without ritonavir (unboosted atazanavir) had statistically lower plasma concentrations than those with ritonavir boosted atazanavir (p = 0.001) and total and indirect bilirubin were statistically associated with plasma concentration of atazanavir (r = 0.32 and r = 0.33 respectively; p < 0.05 in both cases). no statistical association was found among gender, ethnicity, age, weight, body mass index (BMI), lipid profile, and the plasma concentration of atazanavir. CONCLUSION: in summary, as expected, concomitant ritonavir use was the only factor associated with atazanavir plasma levels. prospective studies with a larger sample size might help to observe an association of atazanavir concentrations to other characteristics such as body weight, since the p-value showed to be close to significance (p = 0.068).http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600006&lng=en&tlng=enAtazanavirPlasma levelsDrug concentrationRitonavirLipid profile |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana Júlia Luz Júlia Poeta Rafael Linden Marina Venzon Antunes Luiza Isola Caminha Eduardo Sprinz |
spellingShingle |
Ana Júlia Luz Júlia Poeta Rafael Linden Marina Venzon Antunes Luiza Isola Caminha Eduardo Sprinz Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load Brazilian Journal of Infectious Diseases Atazanavir Plasma levels Drug concentration Ritonavir Lipid profile |
author_facet |
Ana Júlia Luz Júlia Poeta Rafael Linden Marina Venzon Antunes Luiza Isola Caminha Eduardo Sprinz |
author_sort |
Ana Júlia Luz |
title |
Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load |
title_short |
Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load |
title_full |
Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load |
title_fullStr |
Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load |
title_full_unstemmed |
Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load |
title_sort |
related factors to atazanavir plasma levels in a cohort of hiv positive individuals with undetectable viral load |
publisher |
Elsevier |
series |
Brazilian Journal of Infectious Diseases |
issn |
1678-4391 |
description |
OBJECTIVE: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. METHODS: Patients had to be on atazanavir for at least six months, undetectable viral load for a period equal to or longer than 12 months, T CD4+ lymphocyte count higher than 200 cells/mm³, and aged between 18 years and 70 years old. Exclusion criteria were pregnancy, any neurologic disease, active opportunistic disease, hepatitis or cancer. Atazanavir plasma levels were measured by ultra-performance liquid chromatography. RESULTS AND DISCUSSION: Overall, 54 patients (mean age of 47 years and 50% women) were included in the analysis. Those without ritonavir (unboosted atazanavir) had statistically lower plasma concentrations than those with ritonavir boosted atazanavir (p = 0.001) and total and indirect bilirubin were statistically associated with plasma concentration of atazanavir (r = 0.32 and r = 0.33 respectively; p < 0.05 in both cases). no statistical association was found among gender, ethnicity, age, weight, body mass index (BMI), lipid profile, and the plasma concentration of atazanavir. CONCLUSION: in summary, as expected, concomitant ritonavir use was the only factor associated with atazanavir plasma levels. prospective studies with a larger sample size might help to observe an association of atazanavir concentrations to other characteristics such as body weight, since the p-value showed to be close to significance (p = 0.068). |
topic |
Atazanavir Plasma levels Drug concentration Ritonavir Lipid profile |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000600006&lng=en&tlng=en |
work_keys_str_mv |
AT anajulialuz relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload AT juliapoeta relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload AT rafaellinden relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload AT marinavenzonantunes relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload AT luizaisolacaminha relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload AT eduardosprinz relatedfactorstoatazanavirplasmalevelsinacohortofhivpositiveindividualswithundetectableviralload |
_version_ |
1724741601938374656 |